We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07770841

Obesity & weight · Phase 3 · Recruiting now

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841 · Sponsor: Novo Nordisk A/S

What this trial means for you

This study is recruiting now at 16 US sites. It's studying Semaglutide, Placebo for overweight, obesity.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo, diagnosis required
What you'd takeSemaglutide, Placebo
Study length~18 months overall
Planned participants450
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. ≥ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Study sites by state

Alabama

  • Uni of Alabama at Birmingham, Birmingham · Opening soon

California

  • Headlands Research California, LLC, Escondido · Opening soon
  • National Research Institute - Huntington Park, Huntington Park · Opening soon
  • Los Angeles Institute for Metabolic Research, Los Angeles · Opening soon

Florida

  • ERG Holding Company, LLC / Evolution Research Group, LLC, Delray Beach · Opening soon
  • ERG Holding Company, LLC / Evolution Research Group, LLC, Fort Myers · Opening soon
  • Jedidiah Clinical Research, Tampa · Opening soon

Hawaii

  • East West Med Res Inst, Honolulu · Opening soon

Kentucky

  • L-MARC Research Center, Louisville · Opening soon

Missouri

  • StudyMetrix Research LLC, City of Saint Peters · Opening soon

Nevada

  • Jubilee Clinical Research, Inc., Las Vegas · Opening soon

Oregon

  • Corvallis Clinic PC Clinical Research Department, Corvallis · Opening soon

Pennsylvania

  • UPA Ctr Weight and Eating Dis, Philadelphia · Opening soon

South Carolina

  • Spartanburg Medical Research, Spartanburg · Opening soon

Texas

  • Cedar Health Research, Dallas · Opening soon

Virginia

  • Selma Medical Associates, Winchester · Opening soon

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth